LncRNA NEAT1 promotes Brutons tyrosine kinase (BTK) transcription by downregulating the transcription factor Krppel-Like Factor 4 (Klf4), which subsequently leads to the activation of the NF-B pathway, NLRP3 inflammation and M1 polarization in BMDMs, whereas lncRNA NEAT1 from endothelial cells enhances M2 polarization via DDX3X/NLRP3 axis (239, 240)
1000 IU of stable and active Vitamin D3 per drop in a highly bioavailable medium-chain triglyceride base
This includes the key transcription factor nuclear factor kappa B (NF-B), which triggers the infiltration of inflammatory cells in the pancreas and systemic inflammatory response, leading to acinar cell death through apoptosis and necrosis (9)
Disclosures: Eun-Jung Kim: Nothing to Disclose, Dasol Kim: Nothing to Disclose, Banu Akdogan: Nothing to Disclose, Mikkel Holm Vendelbo: Nothing to Disclose, Emilie Munk: Nothing to Disclose, Judith Sailer: Nothing to Disclose, Adriana Filipa Fontes: Nothing to Disclose, Jonas Engler: Nothing to Disclose, Dongsik Park: Nothing to Disclose, Hongjae Lee: Nothing to Disclose, Chunwon Jung: Nothing to Disclose, Byong-Keol Min: Nothing to Disclose, Eok Park: Nothing to Disclose, TaeWon Kim: Nothing to Disclose, Seoyoung Choi: Nothing to Disclose, So-yeon Kim: Nothing to Disclose, Alan DiSpirito: Nothing to Disclose, Thomas Sandahl: Arbormed: Advisor, Orphalan: Speaking and Teaching, Alexion: Grant/Research Support, Univar: Consultant, Ultragenyx: Advisor, Weonbin Im: Nothing to Disclose, So-Young Eun: Nothing to Disclose, Hans Zischka: ArborMed Co., Ltd: Consultant, Valentina Medici: Orphalan: Advisor, Arbormed: Research Grant, Ultragenix: Research Grant, Alexion: Advisor, Vivet: Grant/Research Support 2634 THE IFN-INDUCIBLE MXB LARGE GTPASE ATTENUATES HBV REPLICATION BY ACTIVATING THE RIG-I INNATE IMMUNITY SIGNALING PATHWAY Masazumi Onuki 1 Jun Inoue 1 Masashi Ninomiya 1 Mio Tsuruoka 1 Kosuke Sato 1 Satoko Sawahashi 1 Keishi Ouchi 1 Kengo Watanabe 1 Mark McNiven 2 Atsushi Masamune 1 , 1 Tohoku University Graduate School of Med, 2 Mayo Foundation for Medical Background: Elimination of hepatitis B virus (HBV) from chronically infected patients remains difficult, even though nucleos(t)ide analogs, potent inhibitors of reverse transcription, are widely available
